EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SARS-CoV-2 Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug Resistance

Carlota Fernandez-Antunez iD, Line A Ryberg, Kuan Wang, Long V Pham, Lotte S Mikkelsen, Ulrik Fahnøe, Katrine T Hartmann, Henrik E Jensen, Kenn Holmbeck, Jens Bukh iD, Santseharay Ramirez iD

Viruses · 2025

DOI: 10.3390/v17081055 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Carlota Fernandez-Antunez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, 2650 Hvidovre and Department of Immunolog…. Hauptthemen laut MEDLINE: Adenosine Monophosphate, Drug Resistance, Viral, Alanine, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Candys Foundation, The Region H Foundation, The Novo Nordisk Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Various SARS-CoV-2 remdesivir resistance-associated substitutions (RAS) have been reported, but a comprehensive comparison of their resistance levels is lacking. We identified novel RAS and performed head-to-head comparisons with known RAS in Vero E6 cells. A remdesivir escape polyclonal virus exhibited a 3.6-fold increase in remdesivir EC50 and mutations throughout the genome, including substitutions in nsp12 (E796D) and nsp14 (A255S). However, in reverse-genetics infectious assays, viruses harboring both these substitutions exhibited only a slight decrease in remdesivir susceptibility (1.3-fold increase in EC50). The nsp12-E796D substitution did not impair viral fitness (Vero E6 cells or Syrian hamsters) and was reported in a remdesivir-treated COVID-19 patient. In replication assays, a subgenomic replicon containing nsp12-E796D+nsp14-A255S led to a 16.1-fold increase in replication under remdesivir treatment. A comparison with known RAS showed that S759A, located in the active site of nsp12, conferred the highest remdesivir resistance (106.1-fold increase in replication). Nsp12-RAS V166A/L, V792I, E796D or C799F, all adjacent to the active site, caused intermediate resistance (2.0- to 11.5-fold), whereas N198S, D484Y, or E802D, located farther from the active site, showed no resistance (≤2.0-fold). In conclusion, our classification system, correlating replication under remdesivir treatment with RAS location in nsp12, shows that most nsp12-RAS cause moderate resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenosine MonophosphateDrug Resistance, ViralAlanineAntiviral AgentsSARS-CoV-2COVID-19 Drug TreatmentAnimalsChlorocebus aethiopsVero CellsVirus ReplicationHumansEvolution, MolecularMutationViral Nonstructural ProteinsMesocricetusCOVID-19CricetinaeCoronavirus RNA-Dependent RNA Polymerase

Stichwörter der Autor:innen

DAASARS-CoV-2Vero E6broad-spectrum antiviralfitnesshamstermutationnucleotide analogremdesivirresistance

Substanzen

remdesivirAdenosine MonophosphateAlanineAntiviral AgentsViral Nonstructural ProteinsNSP12 protein, SARS-CoV-2Coronavirus RNA-Dependent RNA Polymerase

Autor:innen und Institutionen

  • Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, 2650 Hvidovre and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University…
  • Department of Veterinary and Animal Sciences, University of Copenhagen, 1870 Frederiksberg, Denmark.

ORCID-Profile: Carlota Fernandez-Antunez, Jens Bukh, Santseharay Ramirez

Förderung

  • Candys Foundation
  • The Region H Foundation
  • The Novo Nordisk Foundation
  • Independent Research Fund Denmark
  • Danish Agency for Science and Higher Education
  • The Mauritzen La Fontaine Fonden
  • Sygeforsikring "danmark"
  • Region H Foundation

Zitieren

APA

Fernandez-Antunez, C., Ryberg, L. A., Wang, K., Pham, L. V., Mikkelsen, L. S., Fahnøe, U., Hartmann, K. T., Jensen, H. E., Holmbeck, K., Bukh, J., & Ramirez, S. (2025). SARS-CoV-2 Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug Resistance. Viruses. https://doi.org/10.3390/v17081055

Vancouver

Fernandez-Antunez C, Ryberg LA, Wang K, Pham LV, Mikkelsen LS, Fahnøe U, et al. SARS-CoV-2 Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug Resistance. Viruses. 2025. doi:10.3390/v17081055

BibTeX
@article{FernandezAntunez2025,
  author = {Fernandez-Antunez, Carlota and Ryberg, Line A and Wang, Kuan and Pham, Long V and Mikkelsen, Lotte S and Fahnøe, Ulrik and Hartmann, Katrine T and Jensen, Henrik E and Holmbeck, Kenn and Bukh, Jens and Ramirez, Santseharay},
  title = {SARS-CoV-2 Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug Resistance},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17081055}
}
Kostenlos starten →